Kornimate/medical-research-clean huggingface dataset:
effect of gnrh agonist vs gnrh antagonist on ivf/icsi outcomes in polycystic ovary syndrome patients.

Conditions: In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility; Polycystic Ovary Syndrome

Summary: this prospective, non-randomised, open-label, clinical trial is conducting on polycystic ovary syndrome (pcos) subjects to compare the effects of two pituitary suppression regimens; gnrh agonist-long protocol and gnrh antagonist-flexible protocol on clinical and embryological ivf/icsi outcomes, and on the follicular fluid levels of placental growth factor (plgf); which is known for his pivotal role in the regulation of ovulation, embryo development, and implantation


Eligibility criteria:
inclusion criteria: * pcos women diagnosed according to the rotterdam criteria undergoing ivf/icsi. * age: 18-39 years. * both ovaries present. exclusion criteria: * age ≥ 40 years. * history of three or more previous ivf failures. * patients with hormonal disorders like hyperprolactinemia, thyroid disorders. * patients who previously undergo unilateral oophorectomy. * patients with chronic diseases: diabetes mellitus, cardiovascular diseases, liver diseases, kidney diseases. * patients with diseases may affect ivf outcomes: endometriosis, uterine fibroids, hydrosalpinx, adenomyosis, autoimmune diseases, * cancer.

Keywords: gnrh agonist gnrh antagonist assisted reproduction technique in vitro fertilization intracytoplasmic sperm injection polycystic ovary syndrome placental growth factor
safety, tolerability, and pharmacokinetics of karxt and dual-burst release of xanomeline with immediate-release trospium chloride in adolescents with psychiatric disorders

Conditions: Psychiatric Disorders

Summary: this study is designed to assess the safety, tolerability, and pharmacokinetics (pk) of multiple doses and ratios of xanomeline and trospium chloride in an ir capsule (karxt) and dual-burst release of xanomeline with immediate-release trospium chloride in adolescents with psychiatric disorders.


Eligibility criteria:
inclusion criteria: * lar (ie, legal guardian or caregiver) must have signed and dated an irb/iec-approved icf in accordance with regulatory, local, and institutional guidelines. * confirmed diagnostic and statistical manual of mental disorders, fifth edition, text revision (dsm-5-tr) psychiatric diagnosis of 1 of the following: 1. schizophrenia or schizoaffective disorder 2. bipolar i or ii disorder 3. attention-deficit/hyperactivity disorder (adhd) 4. tourette's disorder 5. autism spectrum disorder (asd) * participant is judged by the investigator to be clinically stable (eg, no psychiatric hospitalization within the last 6 months; no imminent risk of suicide or injury to self, others, or property). exclusion criteria: * any clinically significant neurological, metabolic (including type 1 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, gi (including active obstructive gi disorders), carcinoma, active biliary disorders (eg, symptomatic gallstones) and/or urological disorder, congestive heart failure (uncontrolled), or cns infection that would pose a risk to the participants if they were to participate in the study or that might confound the results of the study. * participant has a risk for suicidal behavior during the study, as determined by the investigator's clinical judgment and c-ssrs. * egfr \< 60 ml/min. * history of gilbert's disease or history of liver disease (child-pugh class a and higher). * history or high risk of urinary retention, gastric retention, or narrow-angle glaucoma. * participants with history of bladder stones or recurrent utis. * other protocol defined inclusion/exclusion criteria apply.
guideline - based nursing plan for dysphagia after stroke

Conditions: Stroke

Summary: research purposes:1, investigate the nursing management is the head nurse for swallowing disorder after stroke care management status; compared with the existing research, the difference between guidelines and evidence-based nursing plan and the analysis of the influencing factors.2, the investigation nursing personnel for swallowing disorder after stroke nursing implementation status; compare the difference between its and department management requirements and to analyze its influencing factors.3 patients with swallowing disorder after stroke or their caregivers for swallowing disorder after stroke care needs of semi-structured interviews.

research purposes:1, investigate the nursing management is the head nurse for swallowing disorder after stroke care management status; compared with the existing research, the difference between guidelines and evidence-based nursing plan and the analysis of the influencing factors.2, the investigation nursing personnel for swallowing disorder after stroke nursing implementation status; compare the difference between its and department management requirements and to analyze its influencing factors.3 patients with swallowing disorder after stroke or their caregivers for swallowing disorder after stroke care needs of semi-structured interviews.study design.this subject adopts the mixed methods research design, the three parts to complete. research focuses on the 3 armour hospital for ten. the first part first uses the literature analysis method, systematic review of swallowing disorder after stroke related guidelines and research. according to the guidelines and involved in the study of swallowing disorder after stroke care issues related to design the head nurse questionnaire, then cross-sectional investigation understand swallowing disorder after stroke clinical nursing management present situation in our country. according to the regional distribution plans to choose 10 3 armour hospital survey, about 15 head nurse.the second part first uses the literature analysis method, systematic review of swallowing disorder after stroke related guidelines and research. according to the guidelines and involved in the study of brain 4 cross-sectional survey) 108%understanding of the brain in our country。hospital survey,about 250 nurses. the third part uses the qualitative research in the design of phenomenological research methods, through face-to-face semi-structured interviews, collect data, understand the needs of patients and their caregivers, guide the nursing measures of existing. selection of founding of neurology ward patients as the research and interview object, about 20 cases need to sample.

Eligibility criteria:
inclusion criteria: 1. cerebral apoplexy diagnosed by ct or mri; 2. drinking water from depression \> grade 3; 3. be clear and able to communicate; 4. volunteer for the study. exclusion criteria: 1. if you have serious basic diseases such as cardiovascular and cerebrovascular diseases, you cannot cooperate with the examination. 2. the patient refused to accept the investigator.
efficacy of quetiapine for pediatric delirium

Conditions: Delirium

Summary: this study is designed to assess the safety and efficacy of quetiapine as treatment for pediatric delirium.

many children in the icu become confused, due to their underlying illness or treatment effects. the medical term for this confusion is delirium. in adults, a medication called quetiapine has been effective in treating delirium. this is considered an "off label" use as the fda has not approved quetiapine for this indication. pediatricians have been using quetiapine to treat delirium in children as well, but there is currently no data proving that it is effective in children. this study is being done to determine if quetiapine is effective for the treatment of icu delirium in children.

Eligibility criteria:
inclusion criteria: - any patient in the picu aged 1 year to 21 years old who is diagnosed with delirium exclusion criteria: * age \<1 * richmond agitation sedation scale (rass) score of -4 or -5 (deeply sedated or unarousable). * current treatment for alcohol withdrawal * hepatic encephalopathy * pregnancy * diagnosis of major depressive disorder or bipolar disorder * diagnosis of movement disorder * diagnosis of diabetic ketoacidosis * baseline qtc \>500 milliseconds * non-english speaking subjects and/or parent/guardian

Keywords: delirium pediatrics critical care quetiapine
long-term study on home spirometry after lung transplantation

Conditions: Lung Transplantation; Rejection; Death; Bronchiolitis Obliterans

Summary: prospective cohort, mono-center study included electronic data of home spirometry (hs, lung function) of lung transplant recipients

study period between 1/2/2000 and 31/12/2003 follow-up until 31/12/2007 patient will be stratified according to adherence to hs during the first 2 postoperative years good adherent patient: patient performed ≥ 80% of predicted hs within 24 months moderate adherent patient: patient performed ≥ 50% of predicted hs within 24 months non-adherent patient: patient performed \< 50% of predicted hs within 24 months. primary outcome measure graft loss at end of follow-up secondary outcome measure number of acute rejections during follow-up number of hospitalisation during follow-up incidence of bronchiolitis obliterans syndrome during follow-up

Eligibility criteria:
inclusion criteria: * any type of lung transplant incl single, double, combined and re-do * \> 18 years of age * ltx or hltx ≥ 6mts post tx * stable health condition at study entry (pt stays within home environment) * sufficient language skills for amos training * successful amos training * follow-up at our center (≥6 mts post ltx) * willingness to participate by informed consent exclusion criteria: * refused consent * bos diagnosis before study inclusion * malignancy before study inclusion * loss for follow-up (≤ 6 mts after study inclusion

Keywords: lung transplantation home spirometry non-adherence outcomes bronchiolitis obliterans
management of skin graft donor site wound in aged patient

Conditions: Skin Regrafting; Donor Site of Skin Grafting; Vancouver Scar Scale

Summary: the complication of donor site in skin grafting often acts as a causing factor for extended treatment period. the elderly individuals tend to be afflicted by impaired wound healing. herein, the investigators presented the outcome of skin regrafting in the elderly patients.


Eligibility criteria:
inclusion criteria: 1. all patient who need to perform skin grafting surgery exclusion criteria: 1. all patient who cannot be half or general anesthetized 2. severe comorbidities
vr hand exercises: impact on cognition and dexterity in mci

Conditions: Mild Cognitive Impairment (MCI)

Summary: this study aims to investigate the effects of virtual reality (vr)-based hand exercises on cognitive functions and hand skills in older adults with mild cognitive impairment (mci). cognitive functions will be assessed by measuring brain activity using functional near-infrared spectroscopy (fnirs) during the stroop test. additionally, hand functions will be evaluated using the minnesota manual dexterity test, grip strength measurement (via a jamar dynamometer), and the duruöz hand index. hand dominance will be determined using the edinburgh handedness inventory, and sociodemographic data will be collected through a form prepared by the researcher. based on a g\*power analysis, a total of 30 participants-15 in each group-will be included in the study, with an effect size of 1.00094 and a power of 80%. evaluations will be conducted twice, before and after the intervention. to avoid participant fatigue, assessments will be divided over two days. the intervention group will receive vr-based hand exercises twice a week for six weeks. these exercises will include activities such as masterchef (cutting, mixing, and grasping in a virtual kitchen), pinchpeg (placing pegs using pinch grip), holdandput (transporting cups or cans), and bpuzzle (color matching and puzzle completion). the control group will perform traditional exercises twice a week for six weeks, including 30-50 piece puzzle completion, the nine-hole peg test, shape cutting, and number-color matching tasks. the study will be conducted with volunteer participants at the istanbul metropolitan municipality darülaceze directorate, and written and verbal informed consent will be obtained from all participants in accordance with the principles of the declaration of helsinki.


Eligibility criteria:
inclusion criteria: * aged between 65 and 75 years. * diagnosed with mild cognitive impairment by the institution's physician during routine examination. * ability to understand and follow verbal instructions. exclusion criteria: * presence of neurodegenerative diseases affecting cognitive functions. * auditory or visual impairments that could interfere with rehabilitation implementation and communication. * upper extremity disorders, including severe shoulder, elbow, wrist, or finger impairments, bilateral elbow, hand or wrist fractures, or advanced rheumatoid arthritis. * participation in any rehabilitation program during the study period.

Keywords: virtual reality hand exercise mild cognitive impairment cortical activation hand dextery
study on the pharmacokinetic characteristics of i.v. hepabig injection used for prevention of hepatitis b relapse after liver transplantation

Conditions: Liver Cirrhosis; Chronic Hepatitis B

Summary: an exploratory clinical trial to evaluate the pharmacokinetic characteristics of i.v. hepabig injection used for prevention of hepatitis b relapse after liver transplantation.


Eligibility criteria:
inclusion criteria: * male or female ≤18 years old * patients who understand the informed consent form and signed the form voluntarily * patients who underwent liver transplantation due to hbv related disease and will be treated for prevention of hepatitis b relapse after liver transplantation exclusion criteria: * multi-organ recipient or reimplantation * iga deficiency * serious nephropathy * serious cardiovascular system failure within 6 months * ischemic or hemolytic anemia * condition of immunosuppression and immunodeficiency * hypersensitivity or allergic to blood products * hiv or hcv positive * participation to other clinical trial within 3 months * pregnancy or breast feeding * those who the investigator determines inappropriate to participate
comparative pharmacokinetics of yh14659 in healthy male subjects

Conditions: Acute Coronary Syndrome

Summary: the objective of this study is to compare pharmacokinetics after single oral administration of 2 capsules of yh14659, a fixed-dose combination of clopidogrel and aspirin developed by yuhan corporation versus co-administration of plavix (clopidogrel) and astrix (aspirin) in healthy male volunteers.


Eligibility criteria:
inclusion criteria: * healthy male volunteers of aged between 20 years to 55 years * weight: over 50kg, within ±20% of ideal body weight * have no history of neither congenital nor chronic disease * have no history of abnormal symptoms or opinions as a result of physical examination (medical checkup) * eligible subjects with acceptable medical history, physical examination, laboratory tests, ecg during screening period * subject who has signed on the written consent exclusion criteria: * have a known allergy or hypersensitivity to anti-platelet agents * person with hypotension (sbp ≤ 100mmhg or dbp ≤ 50mmhg) or hypertension (sbp ≥ 150mmhg or dbp ≥ 95mmhg), person whose pulse rate is below 45 or over 100 a minute * have the following abnormal findings on diagnosis; * have ast or alt \> 1.25 times of normal upper limit * have total bilirubin \> 1.5 times of normal upper limit * have higher pt, appt, bt than normal range * have plt below 180,000 or above 350,000 * patients with hemorrhage or predisposition to hemorrhage * have disease or history of stomach or intestinal surgery or resection that would potentially alter absorption of orally administered drugs * have participated in other clinical studies within 3 months prior to the first administration * have used any prescription medications including anti-coagulants, anti-platelet agents, thrombolytic drugs and prostaglandin e1 agents within 2 weeks prior to the first administration or any over-the-counter, non-prescription preparations within 1 week prior to the first administration * patients with aspirin induced asthma(aia) or history of aia * subject who is judged to be ineligible by principal investigator or sub-investigator
pulsar combined with pd-1 ab and chemotherapy plus bev. for crlm

Conditions: Colorectal Cancer Liver Metastasis

Summary: to explore progression-free-survival(fps) of pulsar(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with pd-1 ab and chemotherapy plus bevacizumabfor crlm


Eligibility criteria:
inclusion criteria: 1. age 18-75 years, any gender. 2. pathologically confirmed colorectal cancer with liver metastases (stage m1). 3. karnofsky performance status ≥70. 4. adequate organ function, no contraindications to radiotherapy, or immunotherapy. 5. microsatellite/mismatch repair status mss/pmmr. 6. no prior chemotherapy or any other anti-tumor treatment before inclusion. 7. no prior immunotherapy. 8. ability to comply with the study protocol during the study period. 9. signed written informed consent. exclusion criteria: 1. pregnant or lactating women. 2. pathological diagnosis of signet ring cell carcinoma. 3. history of other malignancies within the past 5 years, except cured skin cancer and cervical carcinoma in situ. 4. uncontrolled epilepsy, central nervous system disorders, or history of psychiatric disorders that, in the opinion of the investigator, may interfere with signing the informed consent form or affect patient compliance with oral medication. 5. clinically significant (i.e., active) cardiac disease, such as symptomatic coronary artery disease, new york heart association (nyha) class ii or greater congestive heart failure, or significant arrhythmias requiring drug intervention (see appendix 12), or history of myocardial infarction within the past 12 months. 6. organ transplant recipients requiring immunosuppressive therapy and long-term steroid users. 7. patients with autoimmune diseases. 8. severe uncontrolled recurrent infections or other severe uncontrolled comorbidities. 9. subjects with baseline hematological and biochemical parameters not meeting the following criteria: hemoglobin ≥90g/l; absolute neutrophil count (anc) .≥1.5×10\^9/l; platelets ≥100×10\^9/l; alt, ast ≤2.5 times the upper limit of normal; alp ≤2.5 times the upper limit of normal; serum total bilirubin \<1.5 times the upper limit of normal; serum creatinine \<1 times the upper limit of normal; serum albumin ≥30g/l. 10. known deficiency of dihydropyrimidine dehydrogenase (dpd). 11. allergy to any investigational drug components.
n-3 and n-6 fatty acids in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: purpose: to investigate into the differential effects of polyunsaturated fatty acids as compared to standard control therapy (olive oil) on disease activity and biochemical parameters in patients with rheumatoid arthritis (ra), resp. psoriasis arthritis (pa).

methods: double-blinded, four-armed randomised controlled trial with 3.0 g/d of either n-3 long chain polyunsaturated fatty acids (lc-pufa) or gamma linolenic acid (gla), resp. the combination of 1.5 g/d of each, resp. 3.0 g/d of olive oil over 12 weeks. outcome parameters disease activity score (das28), c-reactive protein, concentrations of n-3 lc-pufa, resp. gla in plasma lipids (pl), cholesterol esters (ce), and erythrocyte membranes (em), and serum concentrations of arachidonic acid (aa). conventional antirheumatic and immunosuppressive therapies could be changed only within defined limits.

Eligibility criteria:
inclusion criteria: * rheumatoid or psoriasis arthritis exclusion criteria: * severe diseases of heart, liver, lung airways * non-compliance

Keywords: n-3 fatty acids n-6 fatty acids anti-inflammatory action clinical trial randomized double-blinded incorporation of fatty acids
point-of-care ultrasound for clean-catch urine collection in young children

Conditions: Urinalysis; Children

Summary: background: the investigators recently evaluated a new bladder stimulation technique to obtain clean-catch urine in infants aged less than six months. in this study, the reported success rate was of 52%. measuring the transversal bladder diameter prior to the procedure with emergency point-of-care ultrasound (epocus) could likely increase success rates for this technique as it has been described for bladder scans prior to performing urethral catheterization. objective: the aim of this study is to evaluate if using emergency point-of-care ultrasound to measure bladder volume improves clean-catch urine collection success in patients less than 6 months of age when compared to children undergoing this technique without a prior ultrasound. methods: this will be a randomized controlled trial performed in a tertiary paediatric emergency department. participants will include all infants younger than 6 months of age who need a urinary culture and/or analysis requested by the attending physician. the intervention will consist of the use of emergency point-of-care ultrasound by a trained research assistant. the primary outcome will be the rate of success of the procedure. secondary objectives will be to evaluate time to collect urine samples and to determine which transversal bladder diameter correlates with more than a 90% success rate for the procedure. independent variables will be sex and age. in both groups, trained research nurses will collect clean-catch urine samples using bladder stimulation techniques. the success rate of the ccu procedure in both groups will be calculated. the time required to collect urine samples will be analysed. in group 1, the investigators will determine the transversal bladder diameter corresponding to a success rate for the procedure of \> 80%. it is estimated that, in the worse-case scenario, the evaluation of 200 participants will provide a 95% confidence interval smaller than 10% for proportions. in addition, 20 participants with a successful ccu sample would allow to evaluate 2 risk factors using univariate and multivariate analysis. expected results: this study will demonstrate that use of emergency point-of-care ultrasound increases success rates of stimulated clean-catch manoeuvres and may avoid invasive urethral catheterizations in young children.


Eligibility criteria:
inclusion criteria: * children aged less than 6 months * urine sample ordered by the treating physician * presence of a research assistant exclusion criteria: * any medical condition where obtaining a midstream urine sample is impossible (e.g. urostomy, anuria for 24h) * any serious illness or unstable infant (e.g. sepsis) * any medical situation where the infant cannot be fed (e.g npo order, gcs\<15) * inability to obtain parental informed consent (language barrier, absence, etc.)